Targeting protein-protein interaction interfaces in COVID-19 drug discovery

Targeting protein-protein interaction interfaces in COVID-19 drug discovery

Blog Article

To date, the COVID-19 pandemic has claimed over 1 million human lives, infected another 50 million individuals and wreaked havoc on the global economy.The crisis has spurred the ongoing Electrical and Ignition development of drugs targeting its etiological agent, the SARS-CoV-2.Targeting relevant protein-protein interaction interfaces (PPIIs) is a viable paradigm for the design of antiviral drugs and enriches the targetable chemical space by providing alternative targets for drug discovery.

In this review, we will provide a comprehensive overview of the theory, methods and applications of PPII-targeted drug development towards COVID-19 based on recent literature.We will also highlight novel developments, such as the successful use of non-native protein-protein interactions as targets for antiviral drug screening.We hope that this review may serve as an entry point for those interested in applying #Youth Barrel Saddle PPIIs towards COVID-19 drug discovery and speed up drug development against the pandemic.